DE · 4AB.DE
AbbVie Inc.
- Sector
- Healthcare · Drug Manufacturers - General
- Headquarters
- North Chicago, IL 60064-6400
- Website
- abbvie.com
Price · as of 2025-12-31
$181.65
Market cap 354.52B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $118.10 | -34.98% |
| Intrinsic Value(DCF) | $89.09 | -50.96% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $33.30 | -81.67% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $12.30 | $34.90 | |||
| 2012 | $12.80 | $38.00 | |||
| 2013 | $0.00 | $22.70 | |||
| 2014 | $0.00 | $13.40 | |||
| 2015 | $0.00 | $60.30 | |||
| 2016 | $44.60 | $59.57 | $49.70 | $0.00 | $63.20 |
| 2017 | $71.10 | $68.26 | $51.10 | $0.00 | $50.40 |
| 2018 | $60.77 | $65.99 | $28.50 | $0.00 | $77.00 |
| 2019 | $60.04 | $90.64 | $29.55 | $0.00 | $43.90 |
| 2020 | $72.99 | $81.63 | $92.45 | $0.00 | $98.50 |
| 2021 | $116.99 | $106.97 | $327.50 | $0.00 | $165.80 |
| 2022 | $124.70 | $108.49 | $219.62 | $0.00 | $65.00 |
| 2023 | $153.40 | $108.18 | $7.19 | $0.00 | $4.70 |
| 2024 | $189.02 | $124.34 | $0.00 | $0.00 | $24.40 |
| 2025 | $199.60 | $138.22 | $6.72 | $0.00 | $33.30 |
AI valuation
Our deep-learning model estimates AbbVie Inc.'s (4AB.DE) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $118.10
- Current price
- $181.65
- AI upside
- -34.98%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$89.09
-50.96% upside
Graham-Dodd
—
— upside
Graham Formula
$33.30
-81.67% upside
About AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
- CEO
- Robert A. Michael
- Employees
- 55K
- Beta
- 0.33
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($89.09 ÷ $181.65) − 1 = -50.96% (DCF, example).